Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen

Cancer Immunology, Immunotherapy

Volumn 58, Issue 12, 2009, Pages 2039-2049

  Li, Fan ^a,b   Yang, Di ^a   Wang, Yiqin ^a   Liu, Baohua ^b   Deng, Yijing ^a,c   Wang, Li ^a   Shang, Xiaoyun ^a   Tong, Weidong ^b   Ni, Bing ^a   Wu, Yuzhang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Altered peptide ligands; Cancer immunotherapy; Cytotoxic T lymphocyte; Epitope; Ran

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; MEMBRANE ANTIGEN; PEPTIDE FRAGMENT; RAN PROTEIN;

ANIMAL; ARTICLE; CELL LINE; CHEMICAL STRUCTURE; CYTOTOXIC T LYMPHOCYTE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; MOUSE; RAT; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, SURFACE; CELL LINE; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; RAN GTP-BINDING PROTEIN; RATS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79958161587     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0712-9     Document Type: Article

References (51)

1. Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281-287
2. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380-384
3. Ribas A, Butterfield LH, Glaspy JA, Economou JS (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21:2415-2432 (Pubitemid 46621880)
4. Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630-641
5. Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T, Katagiri K, Nishikori M, Sukehiro A, Nakagawa M, Yamada A, Aizawa H, Shirouzu K, Itoh K, Yamana H (2003) Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 94:548-556 (Pubitemid 36849721)
6. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187-207 (Pubitemid 40174238)
7. Weis K (2003) Regulating access to the genome: nucleocytoplasmic transport throughout the cell cycle. Cell 112:441-451
8. Kunzler M, Hurt E (2001) Targeting of Ran: variation on a common theme? J Cell Sci 114:3233-3241 (Pubitemid 33009261)
9. Kierszenbaum AL, Gil M, Rivkin E, Tres LL (2002) Ran, a GTP-binding protein involved in nucleocytoplasmic transport and microtubule nucleation, relocates from the manchette to the centrosome region during rat spermiogenesis. Mol Reprod Dev 63:131-140 (Pubitemid 34831323)
10. Li HY, Zheng Y (2004) Phosphorylation of RCC1 in mitosis is essential for producing a high RanGTP concentration on chromosomes and for spindle assembly in mammalian cells. Genes Dev 18:512-527
11. Zhang C, Clarke PR (2000) Chromatin-independent nuclear envelope assembly induced by Ran GTPase in Xenopus egg extracts. Science 288:1429-1432 (Pubitemid 30366330)
12. Hetzer M, Bilbao-Cortes D, Walther TC, Gruss OJ, Mattaj IW (2000) GTP hydrolysis by Ran is required for nuclear envelope assembly. Mol Cell 5:1013-1024
13. Vasu SK, Forbes DJ (2001) Nuclear pores and nuclear assembly. Curr Opin Cell Biol 13:363-375 (Pubitemid 32429503)
14. Kornbluth S, Dasso M, Newport J (1994) Evidence for a dual role for TC4 protein in regulating nuclear structure and cell cycle progression. J Cell Biol 125:705-719 (Pubitemid 24151168)
15. Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y, Yao A, Hirai T, Takabayashi A, Shichijo S, Itoh K (2004) Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients. Clin Cancer Res 10:6695-6702 (Pubitemid 39346567)
16. Shieh DC, Lin DT, Yang BS, Kuan HL, Kao KJ (1996) High frequency of HLA-A*0207 subtype in Chinese population. Transfusion 36:818-821
17. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750-1758 (Pubitemid 28110836)
18. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539-2548 (Pubitemid 126450467)
19. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A (1993) Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929-937 (Pubitemid 23270612)
20. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos K (2000) A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 30:3411-3421 (Pubitemid 32005212)
21. Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM (1993) Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23:1215-1219 (Pubitemid 23165680)
22. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175
23. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219 (Pubitemid 30099526)
24. Yang S, Linette GP, Longerich S, Haluska FG (2002) Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol 169:531-539 (Pubitemid 34686176)
25. Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255-258 (Pubitemid 32772607)
26. Tang Y, Lin Z, Ni B, Wei J, Han J, Wang H, Wu Y (2007) An altered peptide ligand for naive cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity. Cancer Immunol Immunother 56:319-329 (Pubitemid 46035902)
27. Zhu B, Chen Z, Cheng X, Lin Z, Guo J, Jia Z, Zou L, Wang Z, Hu Y, Wang D, Wu Y (2003) Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. Clin Cancer Res 9:1850-1857 (Pubitemid 36554613)
28. Ni B, Gao W, Zhu B, Lin Z, Jia Z, Zhou W, Zhao J, Wang L, Wu Y (2005) Induction of specific human primary immune responses to a Semliki Forest virus-based tumor vaccine in a Trimera mouse model. Cancer Immunol Immunother 54:489-498 (Pubitemid 40543688)
29. Ida K, Kawaguchi S, Sato Y, Tsukahara T, Nabeta Y, Sahara H, Ikeda H, Torigoe T, Ichimiya S, Kamiguchi K, Wada T, Nagoya S, Hiraga H, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Ozaki T, Yoshikawa H, Yamashita T, Sato N (2004) Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol 173:1436-1443 (Pubitemid 38924325)
30. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM (2000) Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13:529-538
31. Yu Z, Theoret MR, Touloukian CE, Surman DR, Garman SC, Feigenbaum L, Baxter TK, Baker BM, Restifo NP (2004) Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest 114:551-559 (Pubitemid 39572105)
32. Han JF, Zhao TT, Liu HL, Lin ZH, Wang HM, Ruan ZH, Zou LY, Wu YZ (2006) Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28. Cancer Immunol Immunother 55:1575-1583 (Pubitemid 44327845)
33. Celis E, Fikes J, Wentworth P, Sidney J, Southwood S, Maewal A, Del Guercio MF, Sette A, Livingston B (1994) Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol 31:1423-1430 (Pubitemid 24381799)
34. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043
35. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y (1998) Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58:4895-4901 (Pubitemid 28503687)
36. Xia F, Lee CW, Altieri DC (2008) Tumor cell dependence on Ran-GTP-directed mitosis. Cancer Res 68:1826-1833 (Pubitemid 351416568)
37. Li P, Yu X, Ge K, Melamed J, Roeder RG, Wang Z (2002) Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 161:1467-1474
38. Li SR, Gyselman VG, Dorudi S, Bustin SA (2000) Elevated levels of RanBP7 mRNA in colorectal carcinoma are associated with increased proliferation and are similar to the transcription pattern of the proto-oncogene c-myc. Biochem Biophys Res Commun 271:537-543 (Pubitemid 30444760)
39. Emberley ED, Gietz RD, Campbell JD, HayGlass KT, Murphy LC, Watson PH (2002) RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer. BMC Cancer 2:28
40. Abe H, Kamai T, Shirataki H, Oyama T, Arai K, Yoshida K (2008) High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma. Int J Cancer 122:2391-2397 (Pubitemid 351542348)
41. Loftus DJ, Squarcina P, Nielsen MB, Geisler C, Castelli C, Odum N, Appella E, Parmiani G, Rivoltini L (1998) Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res 58:2433-2439 (Pubitemid 28252705)
42. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327 (Pubitemid 28144091)
43. Huppa JB, Gleimer M, Sumen C, Davis MM (2003) Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol 4:749-755 (Pubitemid 36986758)
44. Shen L, Rock KL (2004) Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A 101:3035-3040 (Pubitemid 38327730)
45. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN (2004) Antigen bias in T cell cross-priming. Science 304:1314-1317 (Pubitemid 38697426)
46. Iero M, Filipazzi P, Castelli C, Belli F, Valdagni R, Parmiani G, Patuzzo R, Santinami M, Rivoltini L (2009) Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? Cancer Immunol Immunother 58:1159-1167
47. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, Lee PP (2003) Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 9:1377-1382 (Pubitemid 37466186)
48. Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, Lee PP (2004) Diversity and recognition efficiency of T cell responses to cancer. PLoS Med 1:e28
49. Houghton CS, Engelhorn ME, Liu C, Song D, Gregor P, Livingston PO, Orlandi F, Wolchok JD, McCracken J, Houghton AN, Guevara-Patino JA (2007) Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine 25:5330-5342 (Pubitemid 46977537)
50. Valmori D, Gervois N, Rimoldi D, Fonteneau JF, Bonelo A, Lienard D, Rivoltini L, Jotereau F, Cerottini JC, Romero P (1998) Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. J Immunol 161:6956-6962 (Pubitemid 28562243)
51. Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N, Romero P (2008) Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 105:3849-3854 (Pubitemid 351723488)